Test management

Weights & Biases Announces W&B Weave - the Lightweight Toolkit for Developers to Deploy Generative AI Applications with Confidence

Retrieved on: 
Thursday, April 18, 2024
Data Management, Other Technology, Technology, Artificial Intelligence, Software, Weave, Test management, Hallucination, Nature, AI, LLM, Machine learning, Workflow, Weight, Behavior

W&B Weave is a lightweight toolkit for software developers who want to deploy generative AI applications with confidence, providing software developers with a system of record for the experimental large language model (LLM) application development process.

Key Points: 
  • W&B Weave is a lightweight toolkit for software developers who want to deploy generative AI applications with confidence, providing software developers with a system of record for the experimental large language model (LLM) application development process.
  • Over the last 6 years, Weights & Biases has enabled the most innovative foundation model builders to create the generative AI industry.
  • While it’s easy to create a generative AI demo, it’s hard to confidently deploy a generative AI application into production given the risks of abuse, misalignment, and hallucinations.
  • “We built Weave for developers to support the scientific workflow of building AI applications,” said Shawn Lewis, CTO at Weights & Biases.

Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease

Retrieved on: 
Monday, April 22, 2024
Cerebrospinal fluid, Protein, Test management, Risk, Blood, Apolipoprotein E, Plasma, MD, PET, AB, Research, Dementia, Quest Diagnostics, Alzheimer's Association, Patient, Physician, CSF, Diagnosis, Biomarker, Risk assessment, DGX, Frontiers, Journal, Deficit spending, Medical imaging

SECAUCUS, N.J., April 22, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.

Key Points: 
  • P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.
  • With a physician's test order, patients may provide a blood draw for testing from any of Quest's 2,000 patient service centers in the United States.
  • "We know diagnosing AD is challenging, and believe our AD Detect™ services can help individuals better understand their possible risk."
  • A leader in neurology, Quest Diagnostics is committed to developing innovative laboratory services to aid in evaluating patient risk of Alzheimer's Disease and other dementias.

Announcement Execution of Memorandum of Understanding for Share Acquisition (Subsidiarization)

Retrieved on: 
Wednesday, April 3, 2024
MOU, Target, Genetic testing, Relaxation, Fetus, Acquisition, Outline, Test management, Woman, Disorder, Transaction, Security (finance)

The Target Company is a company engaged in a prenatal diagnosis business providing genetic testing and analysis services.

Key Points: 
  • The Target Company is a company engaged in a prenatal diagnosis business providing genetic testing and analysis services.
  • We believe that business synergies will be generated as we aim to improve the value of the customer experience.
  • This acquisition is in line with our ongoing strategy of obtaining assets which can contribute to expanding our presence in Japan.
  • Making the Target Company our subsidiary by purchase of shares (cash settlement), share exchange (kabushiki koukan) or other methods, or a combination thereof.

Tata Advanced Systems Limited and Satellogic Announce TSAT-1A Satellite Launch Success

Retrieved on: 
Monday, April 8, 2024
Contracts, Hardware, Robotics, Data Management, Technology, Defense, Security, Satellite, Engineering, Government Technology, Aerospace, Military, Manufacturing, Falcon 9, Partnership, Test management, Integration, SSL (company), Satellogic, Private sector, TASL, AIT, Data collection, IP, Kennedy Space Center, Collection, EO, Tata Advanced Systems, Communications satellite

TSAT-1A has been assembled in TASL’s Assembly, Integration and Testing (“AIT”) plant at its Vemagal facility in Karnataka.

Key Points: 
  • TSAT-1A has been assembled in TASL’s Assembly, Integration and Testing (“AIT”) plant at its Vemagal facility in Karnataka.
  • This achievement follows the collaboration signed between TASL and Satellogic in November 2023, leveraging Satellogic’s expertise to develop and integrate an advanced EO satellite in India and TASL’s capability to undertake complex system integration.
  • Sukaran Singh, Chief Executive Officer and Managing Director, TASL, said, “This milestone shows TASL’s commitment to the space sector.
  • “Congratulations to both teams on the efficient collaboration that brought TSAT-1A to life and ready for launch,” commented Emiliano Kargieman, CEO at Satellogic.

Biswas Family Foundation, Milken Institute Announce $15 Million in Funding for Research at the Intersection of AI and Health

Retrieved on: 
Tuesday, March 12, 2024
Technology, General Health, Infectious Diseases, Foundation, Philanthropy, Science, Biotechnology, Health, Health Technology, Other Philanthropy, Other Science, Research, Other Technology, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, Gladstone Institutes, Diagnosis, Health informatics, Harvard Medical School, Computational biology, SPARC, Transformative use, Test management, Computer science, Data science, Disease, Assistant, Massachusetts Institute of Technology, Associate, Chatbot, Partnership, Genetics, Patient, Common, Artificial intelligence, AI, Doctor of Philosophy, Interpretation, Investment, Stanford University, Milken Institute, Genetic distance, Medical device

The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .

Key Points: 
  • The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .
  • Five multidisciplinary research teams will receive nearly $14 million total in grant funding for projects aiming to drive translational impact and the advancement of artificial intelligence (AI) models in clinical settings for diagnosis and treatment.
  • Additional support to enhance AI and computational biology research, inclusive of a gift to the Arc Institute , marks a total of $15 million in giving for the Biswas Family Foundation for this interdisciplinary field, and the beginning of more support.
  • To learn more about the Transformative Computational Biology Grant Program and to read the Giving Smarter Guide, visit: https://bit.ly/3Vae8Kq .

Global Non-destructive Testing (NDT) Services Industry Report 2023-2030: Growing Use of Robots and Integration of AI Technology in NDT Processes Gaining Momentum - ResearchAndMarkets.com

Retrieved on: 
Monday, March 11, 2024
Technology, Robotics, Artificial Intelligence, Geography, NDT, Growth, William Ewart Gladstone, Calibration, Manufacturing execution system, SGS, AI, Radiography, Test management, Workforce, Aircraft, Fatigue, Inspection, Oil, Ageing

Additionally, the growing use of robots for NDT and the integration of AI technology in the NDT process are prominent trends in the NDT services market.

Key Points: 
  • Additionally, the growing use of robots for NDT and the integration of AI technology in the NDT process are prominent trends in the NDT services market.
  • In 2023, the inspection services segment is expected to account for the largest share of the global NDT services market.
  • In 2023, the ultrasonic testing segment is expected to account for the largest share of the global NDT services market.
  • In 2023, the flaw detection segment is expected to account for the largest share of the global NDT services market.

Children's Hospital of Philadelphia's Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment Earns Two Press Ganey Awards

Retrieved on: 
Thursday, March 28, 2024
Surgeon, SDU, CHOP, Press Ganey Associates, Patient, Periodic function, Pinnacle, MD, Birth, Senior counsel, Hospital, Heart, Excellence, CFDT, Test management, Children's Hospital of Philadelphia, Parent, Nursing

PHILADELPHIA, March 28, 2024 /PRNewswire/ -- The Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment (CFDT) at Children's Hospital of Philadelphia (CHOP) has once again received prestigious recognition from Press Ganey, a healthcare company that evaluates patient satisfaction.

Key Points: 
  • As in 2022, 2021 and 2020, the CFDT won the 2023 Pinnacle of Excellence Award®, a preeminent, competitive achievement for leading healthcare organizations.
  • Presented annually, the award applauds hospitals and health systems that consistently sustain performance year-over-year.
  • "This award underscores the team's dedication to keeping our patients and families at the forefront of every decision and treatment option."
  • The SDU is the world's first birth facility in a pediatric hospital specifically designed for healthy mothers carrying babies with known birth defects.

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Medical Supplies, Health, Medical Devices, Research, Science, Biotechnology, Methylation, Cervical cancer, Woman, ASCL1, Dysplasia, Triage, Partnership, Multiple endocrine neoplasia, Test management, Human papillomavirus infection, Fujirebio, Risk, SCC, Biomarker, RUO, Incidence, Patient, Carcinoma, Carcinogenesis, Gene, HPV, HSIL, Host, Anal cancer, Lithium, DNA methylation, DNA, IVD, Cancer, CIN, Vaccine

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

Bureau Veritas becomes the market leader in Consumer Products Services in Mexico through the acquisition of “ANCE S.A de C.V.”, a leader in the testing and certification services for Electrical and Electronics consumer products

Retrieved on: 
Thursday, February 22, 2024
Supply Chain Management, Consumer Electronics, Retail, Technology, Manufacturing, Other Technology, Other Manufacturing, Acquisition, Bureau Veritas, Final good, Veritas, Growth, TIC, Inspection, Director general, Safety, History, Lighting, Test management, ANCE, Laboratory

ANCE S.A de C.V. is the Mexican leader for conformity assessment covering many segments including electrical and electronic products, household appliances, and lighting and wireless products.

Key Points: 
  • ANCE S.A de C.V. is the Mexican leader for conformity assessment covering many segments including electrical and electronic products, household appliances, and lighting and wireless products.
  • It positions Bureau Veritas Consumer Products Services as the market leader in Mexico.
  • Hinda Gharbi, Chief Executive Officer of Bureau Veritas, commented: “We are delighted to welcome ANCE S.A de C.V. to Bureau Veritas.
  • Jointly, we will offer comprehensive testing, certification and global market solutions that are truly unique in our industry.”

Prancer Enterprise Welcomes Giri Muthukrishnan as Chief Growth Officer

Retrieved on: 
Wednesday, February 14, 2024
SAN, BNY Mellon, AI, IBM, Test management, Fintech, Lead, JPMorgan Chase, Enterprise, Engineering, Organization, BAS, Penetration test, Management

SAN DIEGO, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Prancer Enterprise, a pioneer in Breach and Attack Simulation (BAS) and PTaaS ( Pentest as a Service), is thrilled to announce the appointment of Giri Muthukrishnan as its new Chief Growth Officer. With an illustrious career that spans many highly regulated enterprises such as the US Federal Reserve, JPMorganChase, BNY Mellon, and IBM, Giri brings a wealth of experience in driving strategic, large-scale cyber initiatives to his new role at Prancer.

Key Points: 
  • Prancer Enterprise, a pioneer in Breach and Attack Simulation (BAS) and PTaaS ( Pentest as a Service), is thrilled to announce the appointment of Giri Muthukrishnan as its new Chief Growth Officer.
  • SAN DIEGO, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Prancer Enterprise, a pioneer in Breach and Attack Simulation (BAS) and PTaaS ( Pentest as a Service), is thrilled to announce the appointment of Giri Muthukrishnan as its new Chief Growth Officer.
  • "We are excited to welcome Giri Muthukrishnan to the Prancer team as Chief Growth Officer," said Farshid Mahdavipour, CEO of Prancer Enterprise.
  • With Giri Muthukrishnan at the helm of growth initiatives, the company is set to achieve new heights of success.